Abbott price target lowered to $132 from $140 at Oppenheimer

Oppenheimer lowered the firm’s price target on Abbott (ABT) to $132 from $140 and keeps an Outperform rating on the shares. The firm notes Abbott reported Q4 revenues of $11.46B, vs. its/consensus $11.77B/$11.80B estimates. Oppenheimer’s constructive outlook assumes subsiding non-MedTech headwinds, easier comparisons in FY26, and top-line composite growth ticking up to low-double digits, along with EBIT margins.